In doing so, you need to know that: 1) the patent is decisive 2) Relief is now researching in Germany and is very successful 3) NeuroRx tries to simulate something under ZYESAMI that is actually RLF-100. Therefore, ZYESAMI is unknown to FDA and there is no EUA also. 4) The loss that GEM is currently recording, will be compensated very quickly after Relief receives approval for the "new" RLF-100.
Now the content of Relief's e-mail, dated April 15, 2021, also has a different meaning:
.... and now you should choose with whom you will go on your journey in the future.